4D Molecular Therapeutics (FDMT) News Today $3.06 +0.15 (+5.15%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.98 -0.09 (-2.78%) As of 04/17/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Equities Analysts Offer Predictions for FDMT FY2026 Earnings4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at Leerink Partnrs issued their FY2026 earnings per share estimates for shares of 4D Molecular Therapeutics in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar anticipates thatApril 19 at 8:15 AM | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Average Price Target from AnalystsApril 14, 2025 | americanbankingnews.comNorges Bank Purchases Shares of 500,823 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Norges Bank acquired a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 500,823 shares of the company's stock, valued at approximately $2,790,000.April 13, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of "Moderate Buy" by AnalystsShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have earned an average rating of "Moderate Buy" from the nine research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned aApril 13, 2025 | marketbeat.com4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement GrantsApril 12, 2025 | finanznachrichten.de4DMT Announces New Employment Inducement GrantsApril 11, 2025 | globenewswire.comWeiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Tuesday.April 10, 2025 | marketbeat.com4D Molecular Therapeutics' (FDMT) "Sell (D-)" Rating Reiterated at Weiss RatingsApril 9, 2025 | americanbankingnews.comRaymond James Financial Inc. Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Raymond James Financial Inc. bought a new position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 112,904 shares of the companApril 8, 2025 | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesMarch 27, 2025 | globenewswire.comWeiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)Weiss Ratings reiterated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday.March 24, 2025 | marketbeat.comShort Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Decreases By 15.1%4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 5,240,000 shares, a decline of 15.1% from the February 13th total of 6,170,000 shares. Based on an average daily trading volume, of 906,600 shares, the short-interest ratio is presently 5.8 days. Currently, 12.2% of the company's stock are sold short.March 20, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of "Moderate Buy" from Analysts4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issuedMarch 17, 2025 | marketbeat.com4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdlesMarch 14, 2025 | uk.investing.com4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular DegenerationMarch 12, 2025 | nasdaq.comBank of America Has Lowered Expectations for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock PriceBank of America lowered their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday.March 11, 2025 | marketbeat.com4D Molecular Therapeutics, Inc.: 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDMarch 10, 2025 | finanznachrichten.de4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDMarch 10, 2025 | globenewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Given "Sell (D-)" Rating at Weiss RatingsWeiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for FDMT Earnings4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst J. ScMarch 7, 2025 | marketbeat.comQ1 Earnings Forecast for FDMT Issued By HC Wainwright4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for 4D Molecular Therapeutics in a research report issued on Monday, March 3rd. HC Wainwright analyst M. Caufield anticipates that the companMarch 7, 2025 | marketbeat.comShort Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Drops By 16.6%4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 6,170,000 shares, a decrease of 16.6% from the January 31st total of 7,400,000 shares. Based on an average daily volume of 905,000 shares, the short-interest ratio is currently 6.8 days.March 6, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan CapitalChardan Capital cut their target price on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research report on Tuesday.March 4, 2025 | marketbeat.com4D Molecular Therapeutics (FDMT) Gets a Buy from BarclaysMarch 4, 2025 | markets.businessinsider.comRoyal Bank of Canada Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $35.00Royal Bank of Canada reduced their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a report on Monday.March 3, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday.March 3, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Releases Earnings Results, Misses Expectations By $0.10 EPS4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) released its earnings results on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.10).March 1, 2025 | marketbeat.com4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesMarch 1, 2025 | finanznachrichten.de4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesFebruary 28, 2025 | finance.yahoo.com4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming MilestonesFebruary 28, 2025 | globenewswire.com4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday4D Molecular Therapeutics (NASDAQ:FDMT) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hoFebruary 20, 2025 | marketbeat.com4D Molecular Therapeutics' (FDMT) Sell (D-) Rating Reiterated at Weiss RatingsWeiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Wednesday.February 20, 2025 | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesFebruary 19, 2025 | globenewswire.com4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF SuppressionFebruary 18, 2025 | seekingalpha.com144,743 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by Peapod Lane Capital LLCPeapod Lane Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 144,743 shares of the company's stock, valued at approximately $806,000.February 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTFebruary 11, 2025 | prnewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan CapitalChardan Capital lowered their target price on 4D Molecular Therapeutics from $39.00 to $30.00 and set a "buy" rating on the stock in a research note on Tuesday.February 11, 2025 | marketbeat.com4D Molecular Therapeutics (FDMT) Gets a Buy from RBC CapitalFebruary 10, 2025 | markets.businessinsider.comH.C. Wainwright maintains buy on 4D Molecular Therapeutics stockFebruary 10, 2025 | msn.comA Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 AnalystsFebruary 10, 2025 | benzinga.comHC Wainwright Reaffirms Buy Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)HC Wainwright restated a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday.February 10, 2025 | marketbeat.com4D Molecular Therapeutics (FDMT) Receives a Buy from BarclaysFebruary 10, 2025 | markets.businessinsider.com4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMDFebruary 9, 2025 | markets.businessinsider.com4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration ProgramFebruary 8, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTFebruary 4, 2025 | prnewswire.com4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD PopulationJanuary 29, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTJanuary 28, 2025 | prnewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Analysts4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eiJanuary 26, 2025 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)January 22, 2025 | markets.businessinsider.com Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address FDMT Media Mentions By Week FDMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.980.53▲Average Medical News Sentiment FDMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼73▲FDMT Articles Average Week Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMTX News ARVN News QURE News BCYC News URGN News DNA News GHRS News KURA News CRMD News SAGE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
